Announced
Completed
Synopsis
Gelesis, a biotherapeutics company aiming to transform weight management using a proprietary biomimetic superabsorbent hydrogel technology, went public via a SPAC merger with Capstar Special Purpose Acquisition, a blank cheque company sponsored by affiliates of Capstar Partners, in a $1bn deal. "Yishai and the Gelesis team have developed a tremendous solution that is poised to transform the weight management industry. We raised our Capstar SPAC last year with the goal of finding a high-growth, disruptive business that is helping people live a better, healthier life. Gelesis fits that criteria perfectly and we are elated to partner with them as they start their exciting next leg of growth," Steve Hicks, Capstar Chairman and CEO.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.